Accesso
Dott.ssa MARIA CICCONE
 
Data di nascita: 23/09/1975 Qualifica: DIRIGENTE MEDICO
Reparto: EMATOLOGIA Numero di telefono dell'ufficio: 0532 236978
Fax dell'ufficio: 0532 212142 E-Mail: m.ciccone@ospfe.it
 
Titolo di studio:
In 2000 Medical Degree at the University of Ferrara (with a mark of one hundred and ten out of one hundred and ten with honors).
 
Altri titoli di studio/professionali:
09/1989 – 07/1994 Secondary Education Liceo Scientifico “G. Galilei” - Manfredonia – FOGGIA (with a mark of sixty out of sixty). 2000 – 2004 Fellowship in Hematology Molecular research in hematological malignancies; University of Ferrara (with a mark of fifty out of fifty with honors).
 
Esperienze professionali (incarichi):
From 2004 Postdoctoral fellowship (from 2004 to 2010), definitive employer (from 2010) Clinical activities: treatment and follow up of patients affected by hematological malignancies, platelet and coagulation disorders; Clinical research: treatment and follow up of patients enrolled in international and national trials; Laboratory research: molecular cytogenetics in hematological malignancies Azienda Ospedaliero-Universitaria Arcispedale S Anna – Ferrara Hematology From February to June of 2008 Postdoctoral research fellowship at Hemolymphopatology Unit of Prof Pileri, Bologna Laboratory Research: application of FISH on paraffin embedded tissues Azienda Ospedaliero-Universitaria S. Orsola-Malpighi – Bologna Emolymphopathology From July 2013 to June 2014 Postdoctoral Fellowship at Leukemia Department at MD Anderson Medical Center – Houston (Mentorship by Professor Alessandra Ferrajoli) Laboratory Research at Experimenthal Therapeutics (Professor George Calin) and Clinical Observer (at the Leukemia Department) MD ANDERSON CANCER CENTER, Houston, Texas Hematology
Competenze linguistiche:
ENGLISH. Understanding: Listening: Advanced high; Reading: advanced high. Speaking: Spoken interaction: advanced high; spoked production: advanced high. Writing: Advanced high
Competenze nell'uso delle tecnologie:
Working Party Groups for acute leukemias, lymphoproliferative diseases and myelodysplastic syndromes for GIMEMA (Gruppo Italiano delle Malattie Ematologiche dell’Adulto) group. Expert in the management of clinical trials according to GCP. At MDAnderson Cancer Center good experience in drafting of clinical trials. Laboratory research in molecular cytogenetics. Microsoft Office: good. Excel: good. Graphpad: good  
Attività didattica:
Attività scientifica:
1. Cuneo A, Cavazzini F, Ciccone M, Daghia G, Sofritti O, Saccenti E, Negrini M, Rigolin GM. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups. Cancer Med. 2014 Jun;3(3):555-64.Epub 2014 Mar 19. 2. Rossi M, Fuligni F, Ciccone M, Agostinelli C, Righi S, Luciani M, Laginestra MA, Rigolin GM, Sapienza MR, Gazzola A, Mannu C, Cuneo A, Pileri S, Piccaluga PP. Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia. Biomed Res Int. 2013; Epub 2013 Dec 12. 3. Rigolin GM, Saccenti E, Rizzotto L, Ferracin M, Martinelli S, Formigaro L, Cibien F, Cavallari M, Lista E, Daghia G, Sofritti O, Ciccone M, Cavazzini F, Lupini L, Bassi C, Zagatti B, Negrini M, Cuneo A. Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. Oncotarget. 2013 Oct 30. [Epub ahead of print] 4. Rizzotto L, Saccenti E, Sofritti O, Daghia G, Volta E, Caprini E, Lupini L, Tammiso E, Bardi A, Lista E, Ciccone M, Russo G, Negrini M, Cuneo A, Rigolin GM. BCR/ABL1-positive acute lymphoblastic leukemia relapsing as BCR/ABL1-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2013 Feb 5 (Epub ahead of print). 5. Rigolin GM, Cibien F, Martinelli S, Formigaro L, Rizzotto L, Tammiso E, Saccenti E, Bardi A, Cavazzini F, Ciccone M, Nichele I, Pizzolo G, Zaja F, Fanin R, Galieni P, Dalsass A, Mestichelli F, Testa N, Negrini M, Cuneo A. Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. Blood. 2012;119(10):2310-3. 6. Ciccone M, Agostinelli C, Rigolin GM, Piccaluga PP, Cavazzini F, Righi S, Sista MT, Sofritti O, Rizzotto L, Sabattini E, Fioritoni G, Falorio S, Stelitano C, Olivieri A, Attolico I, Brugiatelli M, Zinzani PL, Saccenti E, Capello D, Negrini M, Cuneo A, Pileri S. Proliferation centers in chronic lymphocytic leukemia: correlation with cytogenetic and clinicobiological features in consecutive patients analyzed on tissue microarrays. Leukemia. 2012 Mar;26(3):499-508. doi: 10.1038/leu.2011.247. Epub 2011 Sep 23 7. Cavazzini F, Rizzotto L, Sofritti O, Daghia G, Cibien F, Martinelli S, Ciccone M, Saccenti E, Dabusti M, Elkareem AA, Bardi A, Tammiso E, Cuneo A, Rigolin GM. Clonal evolution including 14q32/IGH translocations in chronic lymphocytic leukemia: analysis of clinicobiologic correlations in 105 patients. Leuk Lymphoma. 2012; 53(1):83-8. 8.Ferracin M, Zagatti B, Rizzotto L, Cavazzini F, Veronese A, Ciccone M, Saccenti E, Lupini L, Grilli A, De Angeli C, Negrini M, Cuneo A. MicroRNAs involvement in fludarabine refractory chronic lymphocytic leukemia. Mol Cancer. 2010; 26;9:123. 9. Rigolin GM, Maffei R, Rizzotto, Ciccone M, Sofritti O, Daghia G, Cibien F, Cavazzini F, Marasca R, Cuneo A. Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biological significance. Cancer. 2010; 116(8):1926-37. 10. Cavazzini F, Bardi A, Ciccone M, Rigolin GM, Gorello P, La Starza R, Mecucci C, Cuneo A. Trisomy 8 in PDGFRB-negative cells in a patient with imatinib-sensitive chronic myelomonocytic leukemia and t(5;16)(q33;p13), PDGFRB-NDE1 fusion. Cancer Genet Cytogenet. 2009; 194(1):67-69. 11. Ciccone M, Rigolin GM, Viglione GM, Borrelli M, Serino ML, Cuneo A. thrombosis of the cerebral veins and sinuses in acute promyelocytic leukemia after all-trans retinoic acid treatment: case report. Blood Coagul Fibrinolysis. 2008; 19(7):721-3. 12. Della Porta MG, Malcovati L, Rigolin GM, Rosti V, Bonetti E, Travaglino E, Boveri E, Gallì A, Boggi S, Ciccone M, Pramparo T, Mazzini G, Invernizzi R, Lazzarino M, Cazzola M. immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndrome. Leukemia. 2008; 22(3):530-7. 13. Rigolin GM, Mauro E, Ciccone M, Sofritti O, Castaldi G, Cuneo A. Neoplastic circulating endothelial-like cells in patients with acute myeloid lekaemia. Eur J Haemat. 2007; 78(5):365-373. 14. Mauro E, Rigolin GM, Fraulini F, Sofritti O, Ciccone M, De Angeli C, Castaldi GL, Cuneo A. Mobilization of endothelial progenitor cells in patients with haematological malignancies after treatment with filgrastim and chemiotherapy for autologous transplantation. Eur J Hemat. 2007; 78(5):374-380. 15. Cavazzini F, Bardi A, Tammiso E, Ciccone M, Russo-Rossi A, Divona D, Lo Coco F, Hernandez JM, Wlodarska I, Hagemaijer A, castaldi G, Cuneo A. validation of an interphase fluorescence in situ hybridization approach for the detection of MLL gene rearrangements and of the MLL/AF9 fusion in acute myeloid leukemia. Haematologica. 2006; 91(3):381-385. 16. Ciccone M, Cavazzini F, Castoldi GL Cytogenetics and molecular cytogenetics in diagnosis and prognosis of haematological malignancies. Trends Med. 2006; 6(1):41-55. 17. Rigolin GM, Fraulini C, Ciccone M, Mauro E, Bugli AM, de Angeli C, Negrini M, Cuneo A, Castaldi GL. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2006; 107(6): 2531-2535. 18. Rigolin GM, Porta MD, Bugli AM, Castagnari B, Mauro E, Bragotti LZ, Ciccone M, Cuneo A, Castoldi G. Flow cytometric detection of accelerated telomere shortening in myelodisplastic syndromes: correlations with aetiological and clinical-biological findings. Eur J Haematol. 2004; 73(5):351-358. 19. Rigolin GM, Della Porta M, Ciccone M, Bugli AM, Zenone Bragotti L, Mauro E, Fraulini C, Russo Rossi A, Bardi A, Cuneo A, Castoldi G. In patients with myelodysplastic syndromes response to rHuEPO and G-CSF treatment is related to an increase of cytogenetically normal CD34+ cells. Br J Haematol. 2004; 126(4):501-507. 20. Della Porta M, Rigolin GM, Alessandrino EP, Maiocchi M, Malcovati L, Vanelli L, Barate C, Rumi E, Ciccone M, Cuneo A, Lazzarino M, Castoldi G. Dendritic cell recovery after allogenic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. Eur J Haematology. 2004; 72(1):18-25. 21. Cuneo A, Rigolin GM, Bigoni R, De Angeli C, Veronese A, Cavazzini F, Bardi A, Roberti MG, Tammiso E, Agostani P, Ciccone M, Della Porta M, Tieghi A, Cavazzini L, Negrini M, Castoldi G. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis Leukemia. 2004; 18(3):476-483. 22. Rigolin GM, Tieghi A, Ciccone M, Zenone Bragotti L, Cavazzini F, Della Porta M, Castagnari B, Carroccia R, Guerra G, Cuneo A, Castoldi G Solubile urokinase-type plasminogen activator receptor (suPAR) as an independent factor predicting worse prognosis and extra bone marrow involvement in multiple myeloma patients. Br J Haematol. 2003; 120(6): 953-959 23. Rigolin GM, Della Porta M, Bigoni R, Cavazzini F, Ciccone M, Bardi A, Cuneo A, Castoldi G. rHuEpo administration in patients with low-risk myelodysplastic syndromes: evaluation of erythroid precursors’ response by FISH on May-Grunwald-Giemsa –stained bone marrow samples. Br J Haematol. 2002; 119(3): 652-659 24. Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Tammiso E, Ciccone M, Mancini M, Nanni M, De Cuia R, Divona D, La StarzaR, Crescenzi B, Testoni N, Rege Cambrin G, Mecucci C, Lo Coco F, Saglio G, Castoldi G. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype Leukemia. 2002; 16:1745-1751
Interessi clinici e/o scientifici: